EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Management of Hepatic Visceral Crisis Using Chemoimmunotherapy in PD-L1-High Metastatic Triple-Negative Breast Cancer: A Case Report

Larisa Maria Badau iD, Paul Epure, Madalin-Marius Margan iD, Andrei Dorin Ciocoiu iD, Gabriel-Mugurel Dragomir iD, Brigitha Vlaicu

Diagnostics · 20.03.2026 · 16 (6) · 924

DOI: 10.3390/diagnostics16060924 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Diagnostics, online erschienen am 20.03.2026. Verfasst von Larisa Maria Badau und 5 weiteren Autor:innen. Beteiligte Einrichtung: Doctoral School in Medicine, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Victor Babes” University of Medicine and Pharmacy Timisoara, Romania.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Patients with metastatic breast cancer and visceral crisis are systematically excluded from clinical trials, leaving clinicians without evidence-based therapeutic guidance. To the best of our knowledge, no published reports have described the use of combined chemo-immunotherapy in mTNBC complicated by hepatic visceral crisis. Case presentation: We report the case of a 45-year-old woman with PD-L1-high recurrent TNBC who presented with acute, life-threatening hepatic failure. Laboratory evaluation revealed marked transaminase elevation, cholestasis, rising bilirubin levels, and clinical deterioration consistent with hepatic visceral crisis. Due to severe hepatic impairment, a sequential therapeutic strategy was adopted: treatment was initiated with dose-reduced weekly paclitaxel (80% of the standard dose), and pembrolizumab (200 mg every three weeks) was introduced at the fourth cycle. Shortly after immunotherapy initiation, the patient experienced rapid clinical improvement accompanied by significant biochemical recovery and radiologic tumor regression. Although disease progression occurred after four months, hepatic visceral crisis did not recur.

Discussion

This case questions the conventional restriction of immunotherapy in the setting of severe hepatic dysfunction. The rapid biochemical recovery observed after pembrolizumab initiation suggests that immunologic antitumor activity may be preserved despite significant hepatic impairment. Furthermore, the high PD-L1 expression in this patient indicates that its predictive value may extend even to the context of visceral crisis.

Conclusions

Our findings suggest that immunotherapy in combination with chemotherapy may represent a feasible therapeutic strategy in selected patients with PD-L1-high mTNBC presenting with hepatic visceral crisis.

Schlagwörter

Stichwörter der Autor:innen

immunotherapymetastatic triple-negative breast cancervisceral crisis

Autor:innen und Institutionen

  • Doctoral School in Medicine, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
  • Department of Oncology, ONCOHELP Hospital Timisoara, Ciprian Porumbescu Street, No. 59, 300239 Timisoara, Romania.
  • Discipline of Hygiene, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
  • "Pius Brinzeu" County Emergency Hospital, 300723 Timisoara, Romania.
  • Department of Public Health and Sanitary Management, "Victor Babes" University of Medicine and Pharmacy, Eftimie Murgu Square No. 2, 300041 Timisoara, Romania.
  • Department of Microscopic Morphology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.

ORCID-Profile: Larisa Maria Badau, Madalin-Marius Margan, Andrei Dorin Ciocoiu, Gabriel-Mugurel Dragomir

Förderung

  • Victor Babes” University of Medicine and Pharmacy Timisoara, Romania

Zitieren

APA

Badau, L. M., Epure, P., Margan, M. M., Ciocoiu, A. D., Dragomir, G. M., & Vlaicu, B. (2026). Management of Hepatic Visceral Crisis Using Chemoimmunotherapy in PD-L1-High Metastatic Triple-Negative Breast Cancer: A Case Report. Diagnostics, 16(6), 924. https://doi.org/10.3390/diagnostics16060924

Vancouver

Badau LM, Epure P, Margan MM, Ciocoiu AD, Dragomir GM, Vlaicu B. Management of Hepatic Visceral Crisis Using Chemoimmunotherapy in PD-L1-High Metastatic Triple-Negative Breast Cancer: A Case Report. Diagnostics. 2026;16(6):924. doi:10.3390/diagnostics16060924

BibTeX
@article{Badau2026,
  author = {Badau, Larisa Maria and Epure, Paul and Margan, Madalin-Marius and Ciocoiu, Andrei Dorin and Dragomir, Gabriel-Mugurel and Vlaicu, Brigitha},
  title = {Management of Hepatic Visceral Crisis Using Chemoimmunotherapy in PD-L1-High Metastatic Triple-Negative Breast Cancer: A Case Report},
  journal = {Diagnostics},
  year = {2026},
  volume = {16},
  number = {6},
  pages = {924},
  doi = {10.3390/diagnostics16060924}
}
Kostenlos starten →